REDEFINE-1: Phase 3 Pivotal Trial (NCT05064293) Study Title: "Efficacy and Safety of CagriSema in Adults With Overweight or Obesity (REDEFINE 1)" Status: Completed (Results Published 2024) Phase: Phase 3 Enrollment: 3,400+ participants Study Period: 2021-2024 Location: Global, 15+ countries Design: Randomized, double-blind, active-controlled Duration: 68 weeks Intervention: CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg) vs
Preparing for a Mounjaro injection Before injecting Mounjaro, there are a few things you need to do to prepare
The article also flags oral supplements for bone health, iron, or vitamin absorption as potentially affected by changes in stomach acid and motility
People with genetic variants affecting NAD+ synthesis may experience prolonged or severe side effects
However, despite only being on the market for a few years and despite only becoming popular the last year, these weight loss drugs are already showing up with complications
Yes, you should disclose any current or previous mental health conditions including depression, anxiety, or suicidal ideation
